Neurogene Inc

The stock maintains a bullish medium- and long-term structure, anchored by rising major moving averages and a sequence of higher lows. A recent pullback into the 9/21 EMA support zone was absorbed, signaling acceptance and a favorable entry bias. RSI holds in neutral territory, avoiding overbought extremes. Execution is recommended now, buying into minor pullbacks toward the EMA support area.

• ↑Consensus price target $84.83 implies 121% upside from $39.63.
• ↑Phase 3 EMBOLDEN trial dosing success strengthens FDA approval path.
• ↓Earnings yield deeply negative and profitability weak, risking cash burn.